Authors
Latest:
5 questions with Yue XiongThe beat on the people, devices, trends, and companies shaping healthcare... with Yue Xiong, PhD, Professor of Biochemistry and Biophysics, UNC Lineberger Comprehensive Cancer Center.
Latest:
Dr. Hoshida on Molecular Subtyping in HCCYujin Hoshida, MD, PhD, discusses molecular subtyping in hepatocellular carcinoma.
Latest:
Dr. Bang on Pembrolizumab for Advanced Gastric CancerYung-Jue Bang, MD, PhD, discusses pembrolizumab for the treatment of advanced gastric cancer. Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.
Latest:
Dr. Song on Zanubrutinib Activity in Relapsed/Refractory MCLYuqin Song, MD, PhD, chief physician and deputy director of the Lymphoma Department at Peking University Cancer Hospital, Beijing, China, discusses the updated data from the phase II trial evaluating the efficacy of zanubrutinib (BGB-3111-206) in patients with relapsed/refractory mantle cell lymphoma.
Latest:
Dr. Nikiforov on Reclassifying Subtype of Thyroid CancerYuri E. Nikiforov, MD, PhD, professor of Pathology, vice chair of the Department of Pathology, director, Division of Molecular & Genomic Pathology, University of Pittsburgh, discusses research that demonstrated the need to reclassify a subtype of thyroid cancer as not cancerous.
Latest:
Immunotherapy Examined as Treatment Option in Locally Advanced Cervical CancerThe notion of commandeering the immune system to treat cancer actually dates back more than a century with intratumoral bacterial injections to try and elicit tumor regression.
Latest:
Dr. Saenger on the Need for Immunotherapy BiomarkersYvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.
Latest:
University of Kentucky Lab Seeks to Decode Epigenetic Signals in CancerAlthough many labs study cancer as an all-or-nothing process, putting all metastable hybrid stages in the same bin, our laboratory at the University of Kentucky is exploring carcinogenesis as a continuum, from initiation through progression to maintenance. This approach has prompted us to focus on the role of epigenetics in cancer development.
Latest:
Dr. Saenger on Immunotherapy Combinations in MelanomaYvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses immunotherapy combinations in melanoma.
Latest:
Matching Ostomy Pouching Systems to Patient NeedThe American Cancer Society estimates that in 2013, 142,820 individuals in the United States will be diagnosed with colorectal cancer and 72,570 with bladder cancer
Latest:
Safety and Efficacy of Axatilimab in Patients With Chronic Graft-Versus-Host Disease (AGAVE-201)Zachariah DeFilipp, MD, presents data from AGAVE-201, a phase 2, open-label, randomized, multicenter study evaluating axatilimab at 3 dose levels in patients with recurrent/refractory chronic graft-versus-host disease (GVHD).
Latest:
Dr. Landman on Delivering Value-Based Care to PatientsZachary C. Landman, MD, clinical fellow in Orthopedic Surgery, Department of Orthopedic Surgery, Massachusetts General Hospital, discusses the process of delivering value-based care to patients with cancer.
Latest:
Cost Versus Quality in Different Sites of Cancer CareMore oncology providers have shifted toward consolidation of practices to remain viable. In the last 4 years, 524 private practices have entered into agreements with or have been acquired by hospitals.
Latest:
Combinations With RT May Improve Immunotherapy ResponseOne potential approach to improving the response to cancer immunotherapies is to combine such treatments with radiotherapy.
Latest:
Dr. Mitri Discusses the Promise of Trastuzumab BiosimilarsZahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the promise of trastuzumab (Herceptin) biosimilars.
Latest:
HER2-low Breast Cancer: Practical Applications of ADC TherapyPractical considerations for the sequencing or combination of novel antibody drug conjugates to optimize outcomes for patients with HER2-low breast cancer.
Latest:
From Bedside to BenchBased on a current laboratory research project, Zarah Dulce F. Lucas, MD, discusses microRNAs and their potential to predict brain metastases in patients with triple-negative and HER2-positive breast cancer.
Latest:
FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic CancerDr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma.
Latest:
Utility of Genome-Wide Association Studies in Pediatric OncologyZhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the utility of genome-wide association studies in pediatric oncology.
Latest:
Dr. Yang on the Efficacy of Immunotherapy in Follicular LymphomaZhi Zhang Yang, MD, assistant professor of Medicine, Mayo Clinic, discusses the expression of LAG-3 defining exhaustion of intratumoral PD-1 antibodies and T cells and correlates poor outcomes in patients with follicular lymphoma.
Latest:
Dr. Bakouny on Understanding the Biology of Translocation RCCZiad Bakouny, MD, MSc, discusses understanding the biology of translocation renal cell carcinoma.
Latest:
Experts Discuss Management of Skin and Mouth TRAEs Associated With EGFR TKIsChristine Lovly, MD, PhD, Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, and Linda Ahn discuss how to approach treatment-related adverse effects of the skin and mouth associated with the use of EGFR TKIs.
Latest:
Key Takeaways for Concurrent Biomarker Testing in NSCLCZofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the critical role of both tissue and liquid biopsies, the necessity of rapid time-to-treatment initiation, and the increasing likelihood of liquid biopsies becoming the standard of care for metastatic non-small cell lung cancer patients in the near future.
Latest:
Dr. Stadler on the Utility of Germline Profiling for Targeted Interventions in Advanced CancerZsofia K. Stadler, MD, discusses a study evaluating the clinical utility of germline mutation profiling of targeted therapeutic interventions in a pan-cancer patient population.
